PRF1 and cancer: It has been shown that tumor-infiltrating Th17 lymphocytes display low expression of activation markers and effector functions, such as HLA-DR, CD25, granzyme B, and perforin, and they do not mediate direct cytotoxic activity targeted against cancer cells.